{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:09:33Z","timestamp":1781258973976,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108932","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:51:03Z","timestamp":1655319063000},"page":"108932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic effect of (5R)-5-hydroxytriptolide (LLDT-8) in SIV infected rhesus monkeys"],"prefix":"10.1016","volume":"110","author":[{"given":"Tingxia","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.108932_b0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14787210.2016.1106937","article-title":"Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects","volume":"14","author":"Cenderello","year":"2016","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2022.108932_b0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/QAD.0b013e32835cb747","article-title":"Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment","volume":"27","author":"Lapadula","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.intimp.2022.108932_b0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAD.0000000000000545","article-title":"The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation","volume":"29","author":"Wada","year":"2015","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.intimp.2022.108932_b0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2022.108932_b0025","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 50 (2010) 1387\u20131396.","DOI":"10.1086\/652283"},{"issue":"4","key":"10.1016\/j.intimp.2022.108932_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1468-1293.2012.01051.x","article-title":"Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study","volume":"14","author":"Weber","year":"2013","journal-title":"HIV Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.108932_b0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrneph.2015.9","article-title":"HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment","volume":"11","author":"Rosenberg","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2022.108932_b0040","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/QAD.0b013e328346be29","article-title":"High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors","volume":"25","author":"Aslangul","year":"2011","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.intimp.2022.108932_b0045","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-01-329060","article-title":"Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders","volume":"118","author":"Piconi","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2022.108932_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2012.6936","article-title":"Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial","volume":"308","author":"Paton","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.intimp.2022.108932_b0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/infdis\/jiu012","article-title":"Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy","volume":"209","author":"Eckard","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108932_b0060","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV."},{"issue":"1","key":"10.1016\/j.intimp.2022.108932_b0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hiv.12171","article-title":"Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy","volume":"16","author":"Routy","year":"2015","journal-title":"HIV Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.108932_b0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","article-title":"Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection","volume":"76","author":"Hsu","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2022.108932_b0075","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/infdis\/jis643","article-title":"Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection","volume":"207","author":"Tabb","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2022.108932_b0080","doi-asserted-by":"crossref","first-page":"e1007268","DOI":"10.1371\/journal.ppat.1007268","article-title":"Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration","volume":"14","author":"Chaudhary","year":"2018","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.intimp.2022.108932_b0085","doi-asserted-by":"crossref","first-page":"e1007246","DOI":"10.1371\/journal.ppat.1007246","article-title":"Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication","volume":"14","author":"Nganou-Makamdop","year":"2018","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.intimp.2022.108932_b0090","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"issue":"13","key":"10.1016\/j.intimp.2022.108932_b0095","doi-asserted-by":"crossref","first-page":"1900319","DOI":"10.1002\/advs.201900319","article-title":"Arsenic trioxide impacts viral latency and delays viral rebound after termination of ART in chronically SIV-infected macaques","volume":"6","author":"Yang","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"issue":"2","key":"10.1016\/j.intimp.2022.108932_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1179\/1528433614Z.0000000005","article-title":"Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety","volume":"16","author":"Li","year":"2015","journal-title":"HIV Clin. Trials."},{"issue":"9","key":"10.1016\/j.intimp.2022.108932_b0105","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/aps.2012.108","article-title":"Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8)","volume":"33","author":"Tang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"13-14","key":"10.1016\/j.intimp.2022.108932_b0110","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.intimp.2005.06.009","article-title":"(5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo","volume":"5","author":"Zhou","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108932_b0115","article-title":"(5R)-5-Hydroxytriptolide (LLDT-8) induces substantial epigenetic mediated immune response network changes in fibroblast-like synoviocytes from rheumatoid arthritis patients","volume":"9","author":"Guo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108932_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.00357","article-title":"Does mucosal B1 activation result in the accumulation of peak igm during chronic intrarectal SIVmac239 exposure to protect chinese-origin rhesus macaques from disease progression?","volume":"11","author":"Cong","year":"2020","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108932_b0125","doi-asserted-by":"crossref","first-page":"e1007552","DOI":"10.1371\/journal.ppat.1007552","article-title":"Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques","volume":"15","author":"Chong","year":"2019","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2022.108932_b0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cell.2021.11.032","article-title":"Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide","volume":"185","author":"Xue","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.108932_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.704449","article-title":"Stage-dependent within-individual comparison reveals SIV-specific activation\/exhaustion shift in rhesus macaques","volume":"12","author":"Tong","year":"2021","journal-title":"Front Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108932_b0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-020-0782-y","article-title":"CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption","volume":"26","author":"Harper","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2022.108932_b0145","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3389\/fimmu.2020.01275","article-title":"Safety and immunological evaluation of interleukin-21 plus anti-alpha4beta7 mAb combination therapy in rhesus macaques","volume":"11","author":"Pino","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108932_b0150","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1172\/JCI81400","article-title":"Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques","volume":"125","author":"Micci","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2022.108932_b0155","doi-asserted-by":"crossref","first-page":"522","DOI":"10.24272\/j.issn.2095-8137.2019.047","article-title":"Superior intestinal integrity and limited microbial translocation are associated with lower immune activation in SIVmac239-infected northern pig-tailed macaques (Macaca leonina)","volume":"40","author":"Zhang","year":"2019","journal-title":"Zool. Res."},{"issue":"2","key":"10.1016\/j.intimp.2022.108932_b0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/ID9.0000000000000015","article-title":"Combination of tripterygium wilfordii hook F with antiretroviral therapy delayed viral rebound in a patient of acute HIV-1 infection","volume":"1","author":"Cao","year":"2021","journal-title":"Infect. Dis. Immun."},{"key":"10.1016\/j.intimp.2022.108932_b0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-981-13-0484-2_7","article-title":"HIV persistence on antiretroviral therapy and barriers to a cure","volume":"1075","author":"Sung","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108932_b0170","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/jac\/dkz138","article-title":"Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)","volume":"74","author":"Castagna","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.intimp.2022.108932_b0175","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1111\/febs.15871","article-title":"Mechanisms of viral persistence in the brain and therapeutic approaches","volume":"289","author":"Nath","year":"2022","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.intimp.2022.108932_b0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.immuni.2012.08.010","article-title":"Redefining the viral reservoirs that prevent HIV-1 eradication","volume":"37","author":"Eisele","year":"2012","journal-title":"Immunity"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:48:58Z","timestamp":1761587338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":36,"alternative-id":["S1567576922004167"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108932","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effect of (5R)-5-hydroxytriptolide (LLDT-8) in SIV infected rhesus monkeys","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108932"}}